Salute e Benessere

SyntheticMR and Philips Announce Expanded Global Partnership for SyMRI 3D

"We are very excited to expand our collaboration with SyntheticMR, aiming to achieve greater results with fewer resources in the field of imaging," says Ruud Zwerink, GM at Philips Healthcare. "Through our partnership, we will provide clinicians and patients with improved, immediate, and distinctive insights that have a considerable impact on diagnosis, treatment planning, and the subsequent care – a previously elusive goal." "We are very excited to expand our…
PR Newswire
30/11/2023

Announcement of change in the total number of votes in AB SKF

AB SKF does not hold any own shares. AB SKF does not hold any own shares. Aktiebolaget SKF (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on30 November 2023at 08.00 CET. For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relations tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail:carl.bjernstam@skf...
PR Newswire
30/11/2023

ZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank…

For more information please contact :Fredrik Nielsen CFO Zinzino +46 707 900 174, email: fredrik.nielsen@zinzino.com For more information please contact: Fredrik Nielsen CFO Zinzino +46 707 900 174, email:fredrik.nielsen@zinzino.com Images for free publication: marketing@zinzino.com Certified Adviser: Carnegie Investment Bank AB (publ) The following files are available for download: View original content:...
PR Newswire
30/11/2023

Nexstim Plc Changes Certified Advisor to Carnegie Investment Bank AB (publ)

Company announcement, Helsinki, 30 November 2023 at 10 AM (EET) Nexstim Plc Changes Certified Advisor to Carnegie Investment Bank AB (publ) Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Nexstim has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as…
Nasdaq GlobeNewswire
30/11/2023

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 30 November 2023 at 10.00 a.m. (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara____________________________________________Person subject to the notification requirementName: Jalovaara, PekkaPosition: Member of the Board/Deputy memberIssuer: BBS-Bioactive Bone Substitutes OyjLEI: 743700BYSBP0PCR6N767Notification type: INITIAL NOTIFICATIONReference number:...
Nasdaq GlobeNewswire
30/11/2023

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

This randomized, double-blind, placebo-controlled study will evaluate setanaxib in approximately 20 patients with a genetic diagnosis of Alport syndrome and significant proteinuria despite treatment with a renin-angiotensin system (RAS) blocker. The duration of treatment is 24 weeks. The objective is to evaluate the safety and tolerability of setanaxib in patients with Alport syndrome, as well as the effect of setanaxib on UPCR and eGFR compared to placebo. This randomized, double-blind,...
PR Newswire
30/11/2023

Aino Health (publ) changes Certified Adviser to Carnegie Investment Bank AB…

Aino Health today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Aino Health has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.The Company's Certified Adviser is Carnegie Investment Bank AB...
Nasdaq GlobeNewswire
30/11/2023

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Sobi Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees acrossEurope,North America, theMiddle East,AsiaandAustralia. In 2022, revenue amounted toSEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at...
PR Newswire
30/11/2023

LifeArc - New UK-India research project trialling easy-to-use test to help fight…

New UK-India research project trialling easy-to-use test to help fight against global threat of antimicrobial resistanceThe second round of the Diagnostics for One Health and User Driven Solutions for Antimicrobial Resistance (DOSA2) Project is a UK-India interdisciplinary research project bringing together 5 leading academic institutions to create innovative and rapid diagnostic solutions to reduce the impact of urinary tract infections (UTI) and drug resistant infections...
Nasdaq GlobeNewswire
30/11/2023

Red Ginseng's Potential as a Natural Treatment for Improving Withdrawal Symptoms…

Prof. Oh's research team, through experiments on mice, confirmed that the experiment group consuming red ginseng showed a 50% reduction in leap behaviors indicating physical dependency compared to the control group during morphine administration. In the conditioned place preference test for evaluating psychological dependency, the red ginseng group scored about three times lower than the control group, significantly reducing psychological dependency caused by drug addiction. Prof. Oh's…
PR Newswire
30/11/2023

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observersCopenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and...
Nasdaq GlobeNewswire
30/11/2023

Statement re DXS Secures Innovate UK grant

DXS INTERNATIONAL PLCDXS Secures Innovate UK grant to advanceits precision medicines AI solution The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems is pleased to announce its success in securing £409,000 of grant funding jointly with Health Innovation East from Innovate UK – the UK's national innovation agency - for further research and development of its Artificial...
Nasdaq GlobeNewswire
30/11/2023

Mithra receives guidance from the FDA for the DONESTA® NDA marketing…

Mithra receives guidance from the FDA for the DONESTA ®NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to target the entire accessible US market of nearly 63 million women between the ages of 45 and 65, pending FDA approvalFollowing FDA advice, preparation of filing is proceeding with a filing date now planned in Q4 2024FDA marketing authorization, contingent upon successful completion of...
Nasdaq GlobeNewswire
30/11/2023

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland. The moratorium, if granted, will provide essential protection, enabling the company...
Nasdaq GlobeNewswire
30/11/2023

Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR |…

Key Takeaways from the Metastatic HER2-Positive Breast Cancer Market Report Discover which therapies are expected to grab the major metastatic HER2-positive breast cancer market share @Metastatic HER2-Positive Breast Cancer Market Report Metastatic HER2-Positive Breast Cancer Overview In 2022, HER2-positive breast cancer affected nearly 100,000 individuals in the seven major markets. It is anticipated that the number of cases in the 7MM will rise during the forecast...
PR Newswire
29/11/2023

Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues…

"We are thrilled with the significant growth we achieved in the third quarter," says Iris Bincovich, CEO of Innocan. "Our strategic focus on the midterm-goal of FDA approvals for our LPT-CBD-loaded liposome platform, alongside the robust sales from our subsidiary, B.I. Sky Global Ltd., have significantly contributed to this increase in both revenue and gross profit. We remain committed to our vision and are optimistic about the future." "We are thrilled with the…
PR Newswire
29/11/2023

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be…

The primary objective of the OPALESCENCE study was to evaluate how CAIX-targeted imaging with PET can be utilised for the diagnosis and staging of TNBC and to develop a deeper understanding of CAIX as a potential therapeutic target in this patient population with a significant unmet medical need. The primary objective of the OPALESCENCE study was to evaluate how CAIX-targeted imaging with PET can be utilised for the diagnosis and staging of TNBC and to develop a deeper understanding of CAIX…
PR Newswire
29/11/2023

RFID in Healthcare Market to Surpass US$ 30.03 Billion by 2030 - Coherent Market…

Increasing need for RFID systems in manufacturing units for improving productivity is expected to drive the market over the forecast period. For instance, in June 2021, according to a research article published by Informs, Inc., a provider of innovative and customized solutions for managing and tracking products and information for customers throughout the world, Radio frequency identification (RFID) technology has proven to be an extremely effective solution, allowing workers to quickly…
PR Newswire
29/11/2023

Unither Pharmaceuticals celebrates 30 years of innovation and expertise

Unither first implemented Blow-Fill-Seal (BFS) technology in 1995, enabling them to manufacture sterile doses of saline solutions, asthma medications, and eye drops. From 1997 onwards, the company developed its international business, first by exporting its products, then by acquiring a factory in the United States in 2013. With the acquisition of Barretos in 2015, Unither gained a foothold in Brazil. Then in 2020, an acquisition in China, inNanjing, consolidated its global footprint. In 2022…
PR Newswire
29/11/2023

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

One of the latest developments from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is an update on its flagship asset, pelareorep, and its ongoing GOBLET Phase 1/2 study. Within its pancreatic cancer segment, the study has delivered plenty of optimistic results, with the latest update coming at the European Society for Medical Oncology (ESMO) Congress 2023, at the IFEMA Madrid Conference Center in Madrid, Spain. One of the latest developments fromOncolytics Biotech Inc.(NASDAQ:ONCY)...
PR Newswire
29/11/2023

King Faisal Specialist Hospital and Research Center Honors Two Decades of…

In conveying appreciation for the unwavering commitment to healthcare, the hospital commemorated the meaningful moments dedicated to enhancing the overall patient experience. The culmination of these efforts has woven a rich tapestry of experience and skills, forming the foundation for the esteemed status King Faisal Specialist Hospital and Research Center holds today.Central to this success is the unwavering commitment to employee development and the cultivation of a robust...
Nasdaq GlobeNewswire
29/11/2023

Urology Devices Market Worth $48.6 Billion | MarketsandMarkets

Browse in-depth TOC on "Urology Devices Market" Browse in-depth TOC on "Urology Devices Market" 159 - Tables 44 - Figures 274 - Pages Urology Devices Market Scope: In 2022, the instruments segment held the largest share of the urology devices market by product segment. The urology devices market is segmented into instruments and consumables & accessories based on products. The instruments segment accounted for the largest share of the urology devices market...
PR Newswire
29/11/2023

Teleradiology Market to Reach $46.7 Billion, Globally, by 2032 at 18.1% CAGR…

Prime Determinants of Growth Prime Determinants of Growth Growing healthcare infrastructure, rise in prevalence of chronic conditions that require accurate and timely diagnoses, and growing awareness regarding the use of teleradiology are the factors that drive the growth of the global teleradiology market. However, stringent regulatory requirements hinder market growth. On the contrary, a rise in healthcare expansion is expected to offer remunerative opportunities for the teleradiology...
PR Newswire
29/11/2023

Analytical Standards Market size worth $ 2.56 Billion, Globally, by 2030 at…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24049 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24049 Browse in-depth TOCon" Analytical Standards Market " 202 - Pages 126 – Tables 37 – Figures Global Analytical Standards Market: Unveiling Pioneering Trends in Precision Experimentation In an era of heightened scrutiny on precision experimentation and stringent regulatory demands, the...
PR Newswire
29/11/2023
Altri  Comunicati